Quanta Therapeutics

About Quanta Therapeutics

Quanta Therapeutics is dedicated to developing best-in-class allosteric inhibitors for RAS-driven cancers. The company focuses on targeting previously undruggable RAS mutations, such as KRASG12D and KRASG12V, in difficult-to-treat cancers like pancreatic, colorectal, lung, and endometrial cancers. Their mission is to broaden the scope of treatable RAS-driven cancers through innovative small molecule therapies and deep biologic insights.

Products & Services

QTX3034:An oral G12D-preferring multi-KRAS inhibitor currently in Phase 1 clinical trials, showing favorable safety and preliminary efficacy in dose expansion cohorts for KRASG12D-mutant pancreatic, colorectal, and endometrial cancers.

QTX3544:An oral G12V-preferring multi-KRAS inhibitor in Phase 1 clinical trials, with preclinical data demonstrating potent, selective, CNS-penetrant properties.

QTX3046:An oral KRASG12D-selective dual-state allosteric inhibitor, with dosing of the first patient announced in a Phase 1/1b clinical trial.

RAS-Partner Discovery Program:A novel program using conformation-sensitive Second Harmonic Generation (SHG) assays for allosteric modulation of signaling complexes in the MAPK pathway, with potential as monotherapies or combination therapies.

Specialties

RAS Biology KRAS Inhibitors Allosteric Small Molecules Cancer Therapy Drug Discovery Medicinal Chemistry Second Harmonic Generation (SHG) Platform

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series D T: - FT: Series D	A: 50700000 MR: - FA: 50.7 million FAN: 50700000	D: 2023-05-22 FD: 2023-05-22	9 investors

Series D Latest

2023-05-22

$50.7M

9 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

P

Perry Nisen

Chief Executive Officer

C

Cameron Pitt

Chief Operating Officer

L

Leonardo Faoro

Chief Medical Officer

V

Vanessa L. Jacoby

Chief Business and Financial Officer

H

Hong Lin

SVP of Drug Discovery

J

Juan Luengo

SVP of Chemistry

View 19 more team members with Pro

Unlock Full Team Directory

Recent News